Century Therapeutics (IPSC) Competitors $0.50 0.00 (-0.72%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$0.50 +0.00 (+0.16%) As of 09/15/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPSC vs. CRBU, BTMD, ACTU, BIOA, TVGN, KYTX, NVCT, MCRB, BDTX, and ELDNShould you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Caribou Biosciences (CRBU), biote (BTMD), Actuate Therapeutics (ACTU), BioAge Labs (BIOA), Tevogen Bio (TVGN), Kyverna Therapeutics (KYTX), Nuvectis Pharma (NVCT), Seres Therapeutics (MCRB), Black Diamond Therapeutics (BDTX), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. Century Therapeutics vs. Its Competitors Caribou Biosciences biote Actuate Therapeutics BioAge Labs Tevogen Bio Kyverna Therapeutics Nuvectis Pharma Seres Therapeutics Black Diamond Therapeutics Eledon Pharmaceuticals Century Therapeutics (NASDAQ:IPSC) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability. Which has more risk & volatility, IPSC or CRBU? Century Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.54, indicating that its stock price is 154% more volatile than the S&P 500. Which has stronger earnings & valuation, IPSC or CRBU? Century Therapeutics has higher earnings, but lower revenue than Caribou Biosciences. Century Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentury Therapeutics$6.59M6.52-$126.57M-$0.29-1.71Caribou Biosciences$9.99M17.06-$149.10M-$1.78-1.03 Is IPSC or CRBU more profitable? Century Therapeutics has a net margin of -19.10% compared to Caribou Biosciences' net margin of -1,800.93%. Century Therapeutics' return on equity of -11.53% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Century Therapeutics-19.10% -11.53% -6.94% Caribou Biosciences -1,800.93%-62.35%-49.65% Does the media refer more to IPSC or CRBU? In the previous week, Century Therapeutics had 2 more articles in the media than Caribou Biosciences. MarketBeat recorded 4 mentions for Century Therapeutics and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.34 beat Century Therapeutics' score of -0.22 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Century Therapeutics Neutral Caribou Biosciences Positive Do institutionals and insiders have more ownership in IPSC or CRBU? 50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 5.0% of Century Therapeutics shares are owned by insiders. Comparatively, 9.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer IPSC or CRBU? Century Therapeutics currently has a consensus target price of $3.75, suggesting a potential upside of 654.22%. Caribou Biosciences has a consensus target price of $6.67, suggesting a potential upside of 264.30%. Given Century Therapeutics' higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Caribou Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Century Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCentury Therapeutics beats Caribou Biosciences on 8 of the 15 factors compared between the two stocks. Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPSC vs. The Competition Export to ExcelMetricCentury TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.26M$2.56B$5.80B$10.16BDividend YieldN/A57.22%5.72%4.60%P/E Ratio-1.7123.4975.1126.39Price / Sales6.52517.90511.76177.24Price / CashN/A27.5625.8129.91Price / Book0.265.4013.456.28Net Income-$126.57M$32.95M$3.29B$270.38M7 Day Performance-1.13%-0.53%0.08%1.89%1 Month Performance-11.50%4.23%4.59%6.01%1 Year Performance-68.73%-2.81%75.30%25.26% Century Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPSCCentury Therapeutics2.073 of 5 stars$0.50-0.7%$3.75+654.2%-68.9%$43.26M$6.59M-1.71170Gap UpCRBUCaribou Biosciences2.7913 of 5 stars$1.81-3.2%$6.67+268.3%-13.7%$174.14M$9.99M-1.02100BTMDbiote2.877 of 5 stars$3.45-0.3%$6.00+73.9%-41.1%$171.06M$197.19M3.83194News CoveragePositive NewsACTUActuate Therapeutics2.5291 of 5 stars$7.94-3.6%$20.33+156.1%-12.6%$170.94MN/A0.0010BIOABioAge Labs0.2034 of 5 stars$5.09+6.9%N/AN/A$170.65MN/A0.00N/ANews CoverageTVGNTevogen Bio2.7942 of 5 stars$0.88+1.5%$10.00+1,037.4%+75.8%$170.43MN/A0.003High Trading VolumeKYTXKyverna Therapeutics2.7765 of 5 stars$3.90-1.0%$16.60+325.6%-45.7%$170.39M$7.03M-1.0696Gap UpNVCTNuvectis Pharma3.4766 of 5 stars$6.40-4.2%$15.33+139.6%-7.2%$170.05MN/A-5.478High Trading VolumeMCRBSeres Therapeutics3.0849 of 5 stars$22.85+18.0%$73.67+222.4%-21.5%$169.49M$126.32M-4.97330Gap UpHigh Trading VolumeBDTXBlack Diamond Therapeutics3.5647 of 5 stars$3.05+3.7%$11.67+282.5%-48.5%$167.39MN/A13.2690Positive NewsELDNEledon Pharmaceuticals3.0313 of 5 stars$2.58-4.8%$10.00+287.6%-7.2%$162.28MN/A-2.2110Short Interest ↓ Related Companies and Tools Related Companies CRBU Alternatives BTMD Alternatives ACTU Alternatives BIOA Alternatives TVGN Alternatives KYTX Alternatives NVCT Alternatives MCRB Alternatives BDTX Alternatives ELDN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPSC) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPSC Stock Alerts